{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:35:29Z","timestamp":1755693329490},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic calcium pyrophosphate crystal arthritis is a clinical consequence of the formation and deposition of these crystals in joints and can result in persistent arthritis. Curative treatment would require the removal of crystals from joints and tissues, but to date all agents tested have proven ineffective. Management of the inflammatory manifestations of chronic calcium pyrophosphate disease includes glucocorticoids, non-steroidal anti-inflammatory drugs, or colchicine, and responses are usually satisfactory. However, in some patients, the response to these agents is poor or they are contraindicated. Methotrexate had been reported as a promising option in small case series; however, in a recent issue of <jats:italic>Arthritis Research &amp; Therapy<\/jats:italic>, a clinical trial failed to confirm the anticipated benefits. Here, we discuss some issues that might have influenced the results of the study, before deciding to abandon methotrexate as a therapeutic option for patients with chronic calcium pyrophosphate arthritis.<\/jats:p>","DOI":"10.1186\/s13075-015-0598-1","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T13:44:49Z","timestamp":1427895889000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?"],"prefix":"10.1186","volume":"17","author":[{"given":"Eliseo","family":"Pascual","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Sivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,1]]},"reference":[{"key":"598_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s13075-014-0458-4","volume":"16","author":"A Finckh","year":"2014","unstructured":"Finckh A, McCarthy GM, Madigan A, van Linthoudt D, Weber M, Neto D, et al. Methotrexate ethotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized cross-over trial. Arthritis Res Ther. 2014;16:458.","journal-title":"Arthritis Res Ther"},{"key":"598_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s11926-008-0037-2","volume":"10","author":"N Announ","year":"2008","unstructured":"Announ N, Guerne PA. Treating difficult crystal pyrophosphate dehydrate deposition disease. Curr Rheumatol Rep. 2008;10:228\u201334.","journal-title":"Curr Rheumatol Rep"},{"key":"598_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/ard.2010.139360","volume":"70","author":"W Zhang","year":"2011","unstructured":"Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition, Part II: management. Ann Rheum Dis. 2011;70:571\u20135.","journal-title":"Ann Rheum Dis"},{"key":"598_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/art.22389","volume":"56","author":"A Chollet-Janin","year":"2007","unstructured":"Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007;56:688\u201392.","journal-title":"Arthritis Rheum"},{"key":"598_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/RHU.0b013e3182611471","volume":"18","author":"M Andres","year":"2012","unstructured":"Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012;18:234\u20136.","journal-title":"J Clin Rheumatol"},{"key":"598_CR6","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1002\/art.23552","volume":"58","author":"TH Doan","year":"2008","unstructured":"Doan TH, Chevalier X, Leparc JM, Richette P, Bardin T. Forestier R; French Society for Rheumatology Osteoarthritis Section, Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum. 2008;58:2210\u20131.","journal-title":"Arthritis Rheum"},{"key":"598_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/ard.62.6.513","volume":"62","author":"RL Neame","year":"2003","unstructured":"Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003;62:513\u20138.","journal-title":"Ann Rheum Dis"},{"key":"598_CR8","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1136\/ard.2005.035386","volume":"64","author":"A Martinez-Sanchis","year":"2005","unstructured":"Martinez-Sanchis A, Pascual E. Intracellular and extracellular CPPD crystals are a regular feature in synovial fluid from uninflamed joints of patients with CPPD related arthropathy. Ann Rheum Dis. 2005;64:1769\u201372.","journal-title":"Ann Rheum Dis"},{"key":"598_CR9","first-page":"40","volume":"14","author":"JP Brasseur","year":"1987","unstructured":"Brasseur JP, Huaux JP, Devogelaer JP, De Deuxchaisnes CN. Articular chondrocalcinosis in seropositive rheumatoid arthritis. Comparison with a control group. J Rheumatol. 1987;14:40\u20131.","journal-title":"J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0598-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0598-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:34:49Z","timestamp":1728923689000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0598-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,1]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0598-1","relation":{},"ISSN":["1478-6354"],"issn-type":[{"type":"electronic","value":"1478-6354"}],"subject":[],"published":{"date-parts":[[2015,4,1]]},"assertion":[{"value":"1 April 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"89"}}